Table 2 The incremental cost-effectiveness results from the private and patient’s perspective and time horizon of 5 years
Histopathology + Stratictye™ | Histopathology | |
|---|---|---|
Total cost | $ 3,359.62 | $ 3,553.28 |
Total cancer cases | 0.31 (31 per 100 patient) | 0.36 (36 per 100 patient) |
Incremental cost | ($ 194.36) | Histopathology + Stratictye™ DOMINATES Histopathology |
Cancer cases avoided | 0.05 | |
ICER | Dominant |